TRDA 17.61 Entrada Therapeutics, Inc.
| Range: | 10.75-18.17 | Vol Avg: | 145467 | Last Div: | 0 | Changes: | 0.97 |
| Beta: | -0.26 | Cap: | 0.62B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 29 2021 | Empoloyees: | 168 | ||
| CUSIP: | 29384C108 | CIK: | 0001689375 | ISIN: | US29384C1080 | Country: | US |
| CEO: | Mr. Dipal Doshi | Website: | https://www.entradatx.com | ||||
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Stock Details
TRDA 18
Entrada Therapeutics price target lowered to $18 from $20 at H.C. Wainwright
Raghuram Selvaraju·Tue Jun 25 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow